H.C. Wainwright launched coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and $24 price target based on a positive outlook for the company’s pipeline. The stock closed at $10.29 on Dec. 17...
Mackie Research Capital established a price target of $10.50 for Medexus Pharmaceuticals (TSXV:MDP) following a 15-for-one reverse stock slated for completion on Dec. 19. Medexus, formerly Pediapharm (TSXV:PDP) also...
Ladenburg Thalmann initiated coverage of Novavax (NASDAQ:NVAX) with a “buy” rating and $3 price target, as “we look for transformational data in the first quarter of 2019.” The stock closed at $2.27 on Dec. 17. Novavax...
H.C. Wainwright downgraded Advaxis (NASDAQ:ADXS) to “neutral” from “buy” and removed its price target after Amgen terminated a development and collaboration agreement on ADXS-NEO, Advaxis’ personalized neoantigen...
Roth Capital Markets launched coverage of CollPlant Holdings (NASDAQ:CLGN) with a “buy” rating and 12-month price target of $7. The stock closed at $4.36 on Dec. 17. CollPlant is the world’s first and only commercial...
Roth Capital Partners raised its price target for Arch Therapeutics (OTCQB:ARTH) to $3 from $2.10 after the FDA cleared the company’s AC5 Topical Gel for use in partial and full-thickness skin wounds, such as pressure...
Canopy Growth (TSX:WEED; NYSE:CGC) entered into a multi-year extraction agreement with Valens GroWorks (CSE:VGW; OTC:MYMSF), a licensed provider of cannabis products and services focused on various extraction...
Leerink Partners launched coverage of Millendo Therapeutics (NASDAQ:MLND) with an “outperform” rating and $24 price target. The stock closed at $9.64 on Dec. 12. Millendo is developing treatments for rare, debilitating...
H.C. Wainwright analyst Ed Arce assumed coverage of Organovo Holdings (NASDAQ:ONVO) with a “buy” rating and price target of $2.50. The stock closed at $1.04 on Dec. 12. Organovo was founded in 2007 as a CRO, offering...
AGP/Alliance Global Partners initiated coverage of DarioHealth (NASDAQ:DRIO) with a “buy” rating and price target of $2.50. The stock closed at 76 cents on Dec. 12. ”DarioHealth is well positioned at the confluence of...